This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Freitas, M V. Articles by Louzada-Júnior, P Search for Related Content PubMed PubMed Citation Articles by Freitas, M V. Articles by Louzada-Júnior, P Social Bookmarking                         What's this?

Is HLA class II susceptibility to primary antiphospholipid syndrome different from susceptibility to secondary antiphospholipid syndrome?

Division of Clinical Immunology, Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

L M da Silva

Division of Clinical Immunology, Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

N HS Deghaide

Division of Clinical Immunology, Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

E A Donadi

Division of Clinical Immunology, Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

P Louzada-Júnior

Division of Clinical Immunology, Department of Clinical Medicine, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil, plouzada{at}fmrp.usp.br

To assess whether the major histocompatibility complex (MHC) profile of patients presenting with primary antiphospholipid syndrome (PAPS) is different from that of patients with secondary antiphospholipid syndrome (SAPS), we studied 123 patients, 34 of whom presented PAPS and 35 SAPS due to systemic lupus erythematosus (SLE), 54 SLE patients without antiphospholipid syndrome (APS), and 166 controls. HLA-DRB1 and DQB1 alleles were typed using amplified DNA hybridized with sequence-specific primers. Compared to controls, PAPS patients exhibited a nonsignificantly increased frequency of DR53-associated alleles, and SAPS patients presented an increased frequency of HLA-DRB1* 03 alleles (corrected P 0.05). In addition, HLA-DRB1* 03 alleles were over-represented in SAPS patients presenting anticardiolipin antibody (aCL) (P_c 0.02), in SLE patients as a whole (P_c < 0.0001), and in SLE patients without APS (P_c 0.02). The frequency of aCL among SLE patients presenting or not HLA-DRB1* 03 alleles was closely similar. A trend to an increase in the frequency of the DQB1* 0604 allele (14.3 versus 4.2%, P 0.03) and of the DQB1*0302 allele (31.4 versus 12.7%, P 0.01) was observedin SAPS. Taken together, these results indicate that the association of SAPS with HLA-DRB1* 03 is due to the association with SLE and is not due to aCL, and suggest that the HLA class II profile of PAPS is different from that of SAPS.

Key Words: anticardiolipin antibodies (aCL) • antiphospholipid syndrome (APS) • Brazilians • HLA

Lupus, Vol. 13, No. 2, 125-131 (2004)
DOI: 10.1191/0961203304lu520oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I Uthman and M Khamashta Ethnic and geographical variation in antiphospholipid (Hughes) syndrome Ann Rheum Dis, December 1, 2005; 64(12): 1671 - 1676. [Abstract] [Full Text] [PDF]